drugset
drugset / Trial / NCT03465891

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

NCT03465891 ↗

Phase 2 Terminated 2 enrolled Memorial Sloan Kettering Cancer Center Genentech, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and effects of atezolizumab with low dose radiation on people with relapsed or refractory follicular lymphoma, In this study, the patient will get either atezolizumab with low dose radiation or, atezolizumab alone. To be better, the atezolizumab and low dose radiation should increase life by 1 year or more compared to the usual approach.

Timeline

Start
2018-03-09
Primary completion
2019-12-17
Completion
2019-12-17

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual and lack of funding.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous

Indications

lymphoma